Medications for opioid use disorder
Pro Research Analysisby 
Searched over 200M research papers
Key Medications for Opioid Use Disorder: Methadone, Buprenorphine, and Naltrexone
The main medications approved for treating opioid use disorder (OUD) are methadone, buprenorphine, and naltrexone. Methadone is a full opioid agonist, buprenorphine is a partial agonist, and naltrexone is an opioid antagonist. Methadone and buprenorphine help by reducing withdrawal symptoms and cravings, while naltrexone blocks the effects of opioids if they are used. Methadone has the strongest evidence for effectiveness and is considered the gold standard, but buprenorphine is also highly effective and has advantages such as easier access in office-based settings and a lower risk of side effects. Naltrexone, especially in its long-acting injectable form, can be effective if patients are able to detox before starting treatment, but adherence is often a challenge with oral naltrexone Bell2020Soyka2025Koehl2019+4 MORE.
Effectiveness and Outcomes of Medication-Assisted Treatment
Medication-assisted treatment (MAT) with these medications at least doubles the chances of opioid abstinence compared to psychosocial treatment alone. Both methadone and buprenorphine increase treatment retention, reduce illicit opioid use, and lower the risk of overdose and death. Extended-release naltrexone is less likely to be misused or diverted and does not carry a risk of overdose, but it is less commonly used due to the need for prior detoxification and lower adherence rates Koehl2019Mancher2019Connery2015+2 MORE.
New Formulations and Second-Line Options
To address issues like poor adherence and misuse, new depot (long-acting injectable) and implant formulations of buprenorphine and naltrexone have been developed. For patients who do not respond to standard treatments, supervised injectable opioid treatments (such as pharmaceutical heroin) and retarded morphine are being explored as second-line options Bell2020Soyka2025.
Barriers to Access and Use: Stigma, Logistics, and Provider Shortages
Despite strong evidence for their effectiveness, these medications are underused. Major barriers include stigma against medication use, logistical challenges (such as time, cost, and regulatory requirements), and a shortage of providers certified to prescribe buprenorphine. Stigma is especially strong against methadone, even though it is the most effective, while naltrexone is often viewed as more acceptable despite being less effective for many patients. These barriers exist at the patient, provider, and system levels and can reinforce each other, making it difficult for people to access and stay in treatment Bell2020Madden2022Blanco2019+1 MORE.
Overdose Prevention: Naloxone
Naloxone is an opioid antagonist used to reverse opioid overdoses. Take-home naloxone programs are an important tool for preventing fatal overdoses and are often provided alongside other OUD treatments .
Future Directions and Research Needs
There is a need to expand access to these medications, reduce stigma, and develop new treatment options. Research is ongoing into new medications, including non-opioid options and improved formulations of existing drugs. Training more healthcare professionals to provide these treatments and developing new models of care are also priorities for improving outcomes for people with OUD Soyka2025Townsend2020Blanco2019+1 MORE.
Conclusion
Medications for opioid use disorder—methadone, buprenorphine, and naltrexone—are proven to save lives and improve recovery outcomes. However, their full potential is limited by stigma, logistical barriers, and lack of access. Addressing these challenges and expanding the use of evidence-based treatments is essential for tackling the opioid crisis and improving the lives of those affected by OUD.
Sources and full results
Most relevant research papers on this topic
Medications for management of opioid use disorder.
Buprenorphine is the preferred medication for opioid use disorder, but its use is limited by the low number of physicians certified to prescribe it.
DOI